Drug Pipeline Pulse Check: Amgen Betting on Bone Drug
Amgen Inc. (AMGN) Amgen this week said it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its denosumab drug to combat bone destruction in cancer patients. The BLA submission summarizes clinical experience from head-to-head trials versus Zometa, or zoledronic acid. Denosumab is meant to target cancer induced bone destruction, or bone metastases. [...]
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here